# EDGAR Filing Document

**Accession Number:** 0001845711
**File Stem:** 0000950170-25-081778
**Filing Date:** 2025-6
**Character Count:** 23644
**Document Hash:** 3afee0403465196993b12d73559e4fab
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-081778.hdr.sgml**: 20250604

**ACCESSION NUMBER**: 0000950170-25-081778

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250604

**DATE AS OF CHANGE**: 20250604

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ATAI Life Sciences N.V.
- **CENTRAL INDEX KEY:** 0001840904
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-93405
- **FILM NUMBER:** 251024269

**BUSINESS ADDRESS:**
- **STREET 1:** WALLSTRASSE 16
- **CITY:** BERLIN
- **STATE:** 2M
- **ZIP:** 10179
- **BUSINESS PHONE:** 49 89 2153 9035

**MAIL ADDRESS:**
- **STREET 1:** WALLSTRASSE 16
- **CITY:** BERLIN
- **STATE:** 2M
- **ZIP:** 10179

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ATAI Life Sciences B.V.
- **DATE OF NAME CHANGE:** 20210115
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Apeiron Investment Group Ltd.
- **CENTRAL INDEX KEY:** 0001845711

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** O1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** BLOCK A, APT.12
- **STREET 2:** IL-PIAZZETTA, TOWER ROAD
- **CITY:** SLIEMA
- **STATE:** O1
- **ZIP:** SLM1605
- **BUSINESS PHONE:** 44 7557 251 563

**MAIL ADDRESS:**
- **STREET 1:** BLOCK A, APT.12
- **STREET 2:** IL-PIAZZETTA, TOWER ROAD
- **CITY:** SLIEMA
- **STATE:** O1
- **ZIP:** SLM1605

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**ATAI Life Sciences N.V.**

*(Name of Issuer)*

**Common Shares**

*(Title of Class of Securities)*

**45822R101**

*(CUSIP Number)*

**Evan S. Simpson**<br>1 New Fetter Lane<br>London X0 EC4A 1AN<br>44 20 795984-26

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**06/02/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **45822R101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Apeiron Investment Group Ltd.** | Name of reporting person<br>**Apeiron Investment Group Ltd.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**O1** | Citizenship or place of organization<br>**O1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**46521717.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**46521717.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**46521717.00** | Aggregate amount beneficially owned by each reporting person<br>**46521717.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**22.1%** | Percent of class represented by amount in Row (11)<br>**22.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

| **CUSIP No.** | **45822R101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Apeiron Presight Capital Fund II, L.P.** | Name of reporting person<br>**Apeiron Presight Capital Fund II, L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1799302.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1799302.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1799302.00** | Aggregate amount beneficially owned by each reporting person<br>**1799302.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.9%** | Percent of class represented by amount in Row (11)<br>**0.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

| **CUSIP No.** | **45822R101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Presight Capital Management I, L.L.C.** | Name of reporting person<br>**Presight Capital Management I, L.L.C.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**—** | Source of funds (See Instructions)<br>**—** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1799302.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1799302.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1799302.00** | Aggregate amount beneficially owned by each reporting person<br>**1799302.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.9%** | Percent of class represented by amount in Row (11)<br>**0.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **45822R101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Fabian Hansen** | Name of reporting person<br>**Fabian Hansen** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**—** | Source of funds (See Instructions)<br>**—** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**—** | Citizenship or place of organization<br>**—** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1799302.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1799302.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1799302.00** | Aggregate amount beneficially owned by each reporting person<br>**1799302.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.9%** | Percent of class represented by amount in Row (11)<br>**0.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

| **CUSIP No.** | **45822R101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Christian Angermayer** | Name of reporting person<br>**Christian Angermayer** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**—** | Source of funds (See Instructions)<br>**—** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**—** | Citizenship or place of organization<br>**—** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**227375.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**46521717.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**227375.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**46521717.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**46749092.00** | Aggregate amount beneficially owned by each reporting person<br>**46749092.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**22.2%** | Percent of class represented by amount in Row (11)<br>**22.2%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Shares

**(b) Name of Issuer:**
ATAI Life Sciences N.V.

**(c) Address of Issuer's Principal Executive Offices:**
Wallstrasse 16, Berlin, 2M, 100179

**Item 5. Interest in Securities of the Issuer**

**(a)**
As of June 4, 2025, the Reporting Persons collectively beneficially own 46,521,717 Common Shares, representing approximately 22.1% of the voting rights attached to the Common Shares.

**(b)**
The following sets forth, as of the date of this Amendment, the aggregate number of Ordinary Shares and percentage of Ordinary Shares beneficially owned by each of the Reporting Persons, as well as the number of Ordinary Shares as to which each Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition of, or shared power to dispose or to direct the disposition of, as of the date hereof, based on 210,330,950 Common Shares outstanding as of June 3, 2025, comprising (i) the 200,337,609 Common Shares outstanding as of May 9, 2025, as reported by the Issuer in its Form 10-Q dated May 14, 2025 and (ii) the 9,993,341 Common Shares issued on June 3, 2025 in connection with an investment in the Issuer by two private investors (the "Pipe Investors"), as reported by the Issuer in its Form 8-K dated June 2, 2025.

																				            Sole	          	Shared		 	     Sole power to                              Shared
													                                                                    power			power			        dispose			                 power
      											   Amount						           to vote or		      to vote or to		         or to direct		                 to dispose or
							                                          beneficially		    Percent	              to direct		      direct the		               the			                      to direct the
Reporting Person							               owned			 of class		        the vote		       vote			             disposition		 		  disposition
Apeiron Investment Group, Ltd.		                                 46,521,717		     22.1%			  0			        46,521,717			    0			                          46,521,717
Apeiron Presight Capital Fund II, L.P.				      1,799,302			 0.9%		            0			        1,799,302			      0			                         1,799,302
Presight Capital Management I, L.L.C.				     1,799,302			0.9%			    0			         1,799,302			      0					         1,799,302
Fabian Hansen									 1,799,302			 0.9%		            0			        1,799,302		               0				     	     1,799,302
Christian Angermayer								46,749,092		      22.2%			227375			46,521,717			  227,375					   46,521,717

Presight II is the record holder of 1,799,302 Common Shares. Apeiron is the record holder of 42,369,415 Common Shares and may be deemed to own an additional 2,353,000 Common Shares underlying convertible notes of the Issuer (the "Convertible Notes"). Christian Angermayer also holds 214,000 vested options that are each exercisable for $5.68 into one Common Share, and 13,375 additional stock options will vest and be exercisable on or about June 9, 2025.

Presight Management is the general partner of Presight II. Apeiron and Fabian Hansen are the managing members of Presight Management. Christian Angermayer is the controlling shareholder of Apeiron.

As a result, each of Presight Management, Apeiron, Mr. Hansen and Mr. Angermayer may be deemed to share beneficial ownership of the securities held by Presight II, and Mr. Angermayer may be deemed to share beneficial ownership of the securities held by Apeiron.

**(c)**
Except as described in this Item 5, none of the Reporting Persons has beneficial ownership of any Common Shares or, except as described in this Schedule 13D, has effected any transaction in the Ordinary Shares during the past 60 days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Item 6 of the Schedule 13D is hereby amended and supplemented by the addition of the following:

Voting Agreement

On June 2, 2025, the Issuer, its directors and the members of the executive team of the Issuer, Beckley Psytech Limited and Apeiron entered into certain voting agreements in connection with the Acquisition. Pursuant to Apeiron's voting agreement with the Issuer (the "Voting Agreement"), Apeiron has agreed to vote (or cause to be voted) all of the Common Shares held by it in favor of certain matters set forth in the Voting Agreement, including to support (i) without limitation, shareholder approvals to approve the transactions contemplated by the share purchase agreement entered into in connection with the Acquisition and (ii) subject to certain conditions, any potential transaction that may be pursued by the Issuer to move the legal and tax domicile of the Issuer from the Netherlands (in respect of its corporate seat) and Germany (in respect of its tax domicile) to Delaware.

The foregoing description of the Voting Agreement does not purport to be complete and is subject to and qualified in its entirety by reference to the full text of the Voting Agreement, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Shareholders Rights Agreement

On June 2, 2025, Apeiron entered into a shareholders rights agreement with the Issuer (the "Rights Agreement"). Under the Rights Agreement, Apeiron will have the right, subject to certain requirements, to select a number of director designees equal to (i) two, for so long as Apeiron and its affiliates beneficially own no less than 12.5% of the equity securities of the Issuer (inclusive of Common Shares issued or issuable in connection with the exercise of options, warrants, rights, units or other securities) and (ii) one, for so long as Apeiron and its affiliates collectively beneficially own at least 7.5% but less than 12.5% of such Issuer equity securities.

Apeiron also entered into a lock-up agreement (the "Lock-Up Agreement") on June 2, 2025 containing customary lock-up terms, pursuant to which Apeiron will, subject to certain exceptions, not transfer any equity securities of the Issuer for a certain specified period. At the expiration of such period, the lock-up restrictions will fall away in part on a monthly basis until the date that is twelve months following the expiration of such period.

The foregoing description of the Rights Agreement and the Lock-Up Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Rights Agreement and the Lock-Up Agreement, copies of which are attached hereto as Exhibits 99.2 and 99.3, respectively, and are incorporated herein by reference.

Registration Rights Agreement

On June 2, 2025, the Issuer entered into a registration rights agreement with Apeiron, Mr. Angermayer and the PIPE Investors (the "Registration Rights Agreement") providing for certain registration rights with respect to Common Shares held by such holders from time to time.

The Registration Rights Agreement requires the Issuer to file a registration statement under the Securities Act of 1933, as amended, providing for the resale of all or part of the registrable securities held by the parties thereto as promptly as practicable and use reasonable best efforts to cause such registration statement to be declared effective within the timelines specified therein, and thereafter to keep such registration statement effective for the periods specified therein.

Apeiron will have customary demand rights that will require the Issuer to file registration statements registering its registrable securities. The Issuer has agreed to reasonably assist and cooperate, including by making management available for an electronic "road show" or other marketing efforts, in block trades and marketed or non-marketed underwritten shelf takedown offerings for sales by Apeiron with an offering price, in the aggregate, of at least $25 million. The Registration Rights Agreement also includes customary piggyback rights for Apeiron, subject to certain priority provisions. The Issuer has agreed to bear all registration expenses, including reasonable and documented fees of one counsel for all the selling shareholders, other than customary underwriting commissions or fees, regardless of whether a registration statement is filed or becomes effective. The Registration Rights Agreement also contains customary indemnity, exculpation and contribution obligations by the Issuer and the other parties to the Registration Rights Agreement.

The foregoing description of the Registration Rights Agreement does not purport to be complete and is subject to and qualified in its entirety by reference to the full text of the Registration Rights Agreement, a copy of which is attached hereto as Exhibit 99.4 and is incorporated herein by reference.

Option Grants

On June 2, 2025, the Issuer granted to Mr. Angermayer in further consideration of his continued service as a consultant and other valuable consideration (i) an option to purchase 337,686 ordinary shares of the Issuer that will vest with respect to 131,698 shares subject to the option based on the Issuer's standard four year vesting schedule and with respect to 205,988 shares subject to the option based on the Issuer achieving asset value goals by December 31, 2026, and (ii) an option to purchase 292,500 shares that will vest based on the Issuer's standard four year vesting schedule. In addition, the options are subject to Mr. Angermayer entering into an amended consultancy agreement that provides for compliance with the Issuer's code of conduct, compliance program and the Voting Agreement.

Other than as described herein, there are no contracts, arrangements, understandings or relationships among the Reporting Persons, or between the Reporting Persons and any other person, with respect to the securities of the Issuer.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Apeiron Investment Group Ltd.

**Signature:** /s/ Mario Frendo

**Name/Title:** Mario Frendo, Director

**Date:** 06/04/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Apeiron Presight Capital Fund II, L.P.

**Signature:** /s/ Fabian Hansen

**Name/Title:** Fabian Hansen, Managing Member

**Date:** 06/04/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Presight Capital Management I, L.L.C.

**Signature:** /s/ Fabian Hansen

**Name/Title:** Fabian Hansen, Managing Member

**Date:** 06/04/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Fabian Hansen

**Signature:** /s/ Fabian Hansen

**Name/Title:** Fabian Hansen

**Date:** 06/04/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Christian Angermayer

**Signature:** /s/ Christian Angermayer

**Name/Title:** Christian Angermayer

**Date:** 06/04/2025